Literature DB >> 10646844

Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.

X P Hao1, J E Willis, T G Pretlow, J S Rao, G T MacLennan, I C Talbot, T P Pretlow.   

Abstract

Abnormal expression of the fragile histidine triad (FHIT) candidate tumor suppressor gene has been observed in a variety of human tumors, but little is known about its expression during colorectal tumorigenesis. Sections of 70 aberrant crypt foci (ACF), 55 adenomas, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically for Fhit expression. All normal colonic epithelium showed a strong expression of Fhit; 44% of carcinomas showed a marked loss or absence of Fhit expression. The proportion of carcinomas with reduced expression showed an increasing trend (a) with decreasing differentiation and (b) in tumors with metastases (62%) compared with tumors without metastases (38%). The proportion of metastatic lesions (12 of 13) with reduced expression of Fhit was even greater. Although only a small proportion of ACF and adenomas showed a reduction of Fhit expression, the reduced expression of Fhit was strongly associated with the degree of dysplasia in both ACF (P = 0.0002) and adenomas (P = 0.0085). The findings of reduced expression of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of primary and metastatic colorectal cancers suggest that Fhit plays a role in the development and progression of some colon carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646844

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.

Authors:  Hong Li; Po Zhao; Yang Lu; Yali Lu
Journal:  Int J Colorectal Dis       Date:  2012-02-09       Impact factor: 2.571

2.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.

Authors:  Xia Chu; Po Zhao; Yali Lv; Lin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

4.  Absence of FHIT expression is associated with apoptosis inhibition in colorectal cancer.

Authors:  Jie Cao; Xiaoping Chen; Wanglin Li; Jie Xia; Hong Du; Weibiao Tang; Shanming Chen; Hui Wang; Xiwen Chen; Huanqing Xiao; Yuyuan Li
Journal:  Front Med China       Date:  2007-05-01

5.  Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.

Authors:  Po Zhao; Yazhuo Li; Yali Lu
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

6.  Aberrant crypt focus and fragile histidine triad protein in sporadic colorectal carcinoma.

Authors:  Kim Vaiphei; Aruna Rangan; Rajinder Singh
Journal:  World J Gastrointest Oncol       Date:  2012-12-15

7.  Human cytomegalovirus-encoded US28 may act as a tumor promoter in colorectal cancer.

Authors:  Zhen-Zhai Cai; Jian-Gang Xu; Yu-Hui Zhou; Ji-Hang Zheng; Ke-Zhi Lin; Shu-Zhi Zheng; Meng-Si Ye; Yun He; Chang-Bao Liu; Zhan-Xiong Xue
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

8.  Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma.

Authors:  Po Zhao; Ying-Chuan Hu; Ian C Talbot
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Reduced Fhit protein expression in human malignant mesothelioma.

Authors:  Lea Pylkkänen; Henrik Wolff; Tuula Stjernvall; Aija Knuuttila; Sisko Anttila; Kirsti Husgafvel-Pursiainen
Journal:  Virchows Arch       Date:  2003-10-16       Impact factor: 4.064

10.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.